We are live on ! Find out more
SGNT

SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT

Delisted

SGNT was delisted on the 29th of August, 2016.

Back to rankings

103 hedge funds and large institutions have $436M invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2013 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 20 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,550% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 2

115% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 20

43% more funds holding

Funds holding: 72 → 103 (+31)

26% more capital invested

Capital invested by funds: $345M → $436M (+$91.1M)

Holders
103
Holders Change
+31
Holders Change %
+43.06%
% of All Funds
3.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
43
Reduced
20
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$87.9M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$8.69M
3
Millennium Management
Millennium Management
New York
+$7.16M
4
PCP
Perimeter Capital Partners
Georgia
+$5.54M
5
OAM
Oxford Asset Management
United Kingdom
+$5.07M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$23.8M
2
VAM
Visium Asset Management
New York
-$11.3M
3
Morgan Stanley
Morgan Stanley
New York
-$9.34M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$7.95M
5
CS
Credit Suisse
Switzerland
-$7.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
76
RhumbLine Advisers
Massachusetts
$296K -$3.18K -143 -1%
VOYA Investment Management
77
VOYA Investment Management
Georgia
$290K – – –
MLICM
78
Metropolitan Life Insurance Company (MetLife)
New York
$285K – – –
NG
79
NatWest Group
United Kingdom
$284K +$17.5K +784 +6%
NFA
80
Nationwide Fund Advisors
Ohio
$282K +$95.3K +4,279 +45%
HHC
81
Hutchin Hill Capital
New York
$259K +$283K +12,700 New
Swiss National Bank
82
Swiss National Bank
Switzerland
$237K +$37.8K +1,700 +17%
AIG
83
American International Group
New York
$228K +$105K +4,724 +73%
ProShare Advisors
84
ProShare Advisors
Maryland
$215K +$235K +10,541 New
SCM
85
Stevens Capital Management
Pennsylvania
$204K +$223K +9,997 New
Bank of Montreal
86
Bank of Montreal
Ontario, Canada
$194K +$211K +9,497 New
BJ
87
BlackRock Japan
Japan
$126K +$33.7K +1,514 +32%
Barclays
88
Barclays
United Kingdom
$106K +$99.1K +4,451 +513%
FMT
89
First Mercantile Trust
Tennessee
$84K +$91.4K +4,105 New
TRCT
90
Tower Research Capital (TRC)
New York
$57K -$15.6K -702 -20%
CAM
91
ClariVest Asset Management
California
$57K +$62.3K +2,800 New
U
92
UBS
Switzerland
$45K +$49.2K +2,212 New
Wells Fargo
93
Wells Fargo
California
$41K +$44.2K +1,986 New
EWM
94
Evercore Wealth Management
New York
$40K – – –
PCM
95
Prelude Capital Management
New York
$32K +$34.5K +1,550 New
MCM
96
Mazama Capital Management
Oregon
$28K -$53.4K -2,400 -63%
Citigroup
97
Citigroup
New York
$28K +$2.2K +99 +8%
PAM
98
Panagora Asset Management
Massachusetts
$27K +$28.9K +1,300 New
Teacher Retirement System of Texas
99
Teacher Retirement System of Texas
Texas
$26K +$13.1K +587 +88%
Ameriprise
100
Ameriprise
Minnesota
$21K – – –
1 2 3
4
5

SGNT Hedge Fund Activity: Q3 2013 in Review

103 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q3 2013, worth a combined $436M — up 26% from $345M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new SGNT positions and 2 closed out — a net gain of 31 holders — while 43 added to existing stakes and 20 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $87.9M. The largest seller was Deerfield Management, cutting an estimated $23.8M.

  • 103 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q3 2013, up from 72 in Q2 2013.
  • Funds reported $436M of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q3 2013, up 26% quarter-over-quarter.
  • 33 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q3 2013 and 2 closed out, a net change of +31 holders.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) buyer in Q3 2013 was Franklin Resources, an estimated $87.9M added.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q3 2013 was Deerfield Management, an estimated $23.8M sold.

Based on aggregated 13F filings for Q3 2013.